In the era of BCR/bcl-2 inhibitors, it has been suggested that historically, poor-risk CLL (e.g., with TP53 mutation) should initially be treated with novel agents and transplanted when this therapy fails or unacceptable toxicities occur. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.